Department of Neurology, CSM Medical University, Lucknow, India.
Top Stroke Rehabil. 2011 Oct;18 Suppl 1:599-610. doi: 10.1310/tsr18s01-599.
The minimal clinically important difference (MCID) estimates of some of the stroke-related measures are available; but MCID of the Fugl-Meyer assessment (FMA) measure is unknown, which limits the application and interpretation of change scores in poststroke patients with motor deficits.
To estimate the MCID of the FMA-UE (upper extremity) using the modified Rankin scale (mRS) and global rating of patient-perceived changes (GRPPC) in subacute poststroke patients.
The prospective, cohort study took place in the neurology department of a university hospital. Seventy-one subacute poststroke (mean duration, 8.42 weeks) patients were prospectively enrolled in a randomized clinical trial of the ongoing Meaningful Task Specific Training (MTST). FMA-UE, mRS, and GRPPC scores were obtained at pre- and 4 weeks postintervention.
The MCID values of FMA-UE were 9 (80.39% sensitive and 70% specific) and 10 (97.62% sensitive and 89.66% specific) anchored to mRS and GRPPC, respectively.
The estimated MCID score for the upper extremity motor recovery among patients with subacute stroke is 9 to 10 on the FMA-UE. Patients with subacute stroke who achieve a score of 9 to 10 on FMA-UE are more likely to experience or perceive a meaningful and clinically important improvement in their disability level than those who do not. The reference value can be used to develop goals and interpret progress in subacute poststroke patients.
一些与中风相关的测量指标的最小临床重要差异(MCID)已经有了估计值;但 Fugl-Meyer 评估(FMA)测量的 MCID 尚不清楚,这限制了在有运动障碍的中风后患者中使用变化分数的应用和解释。
使用改良 Rankin 量表(mRS)和患者感知变化的总体评分(GRPPC)来估计 FMA-UE(上肢)的 MCID,这些患者是亚急性中风后。
这项前瞻性队列研究在一所大学医院的神经科进行。71 名亚急性中风患者(平均病程为 8.42 周)前瞻性地纳入了正在进行的有意义的任务特定训练(MTST)的随机临床试验。在干预前和 4 周后分别获得 FMA-UE、mRS 和 GRPPC 评分。
FMA-UE 的 MCID 值分别为 9(80.39%敏感,70%特异)和 10(97.62%敏感,89.66%特异),分别以 mRS 和 GRPPC 为参照。
亚急性中风患者上肢运动恢复的估计 MCID 分数为 FMA-UE 的 9 到 10。在 FMA-UE 上获得 9 到 10 分的亚急性中风患者,比那些没有达到这个分数的患者更有可能经历或感知到残疾水平的有意义的和临床重要的改善。参考值可用于制定目标和解释亚急性中风后患者的进展。